<DOC>
	<DOCNO>NCT00601094</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gene-modified virus may help body build effective immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient stage IIIB , stage IV , recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage IIIB , Stage IV , Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety , toxicity , maximum tolerate dose ( MTD ) autologous dendritic cell-adenovirus CCL21 vaccine administer intratumoral injection treat patient stage IIIB , IV , recurrent non-small cell lung cancer . Secondary - To determine biologic clinical response therapy . - To determine treatment-related toxicity use NCI Common Toxicity Criteria . - To identify MTD . - To monitor patient evidence autologous dendritic cell-adenovirus CCL21 vaccine-induced cytokine antigen-specific immune response . - To detect immune response tumor-associated antigen vector . - To assess patient objective sign tumor regression ( RECIST Criteria ) . OUTLINE : This dose-escalation study autologous dendritic cell-adenovirus CCL21 vaccine . Patients undergo leukapheresis obtain leukocyte generation autologous dendritic cell ( DC ) . Adenovirus carry CCL21 gene add dendritic cell make vaccine . Approximately 2 week leukapheresis , patient receive intratumoral injection autologous dendritic cell-adenovirus CCL21 vaccine CT-guidance bronchoscopy day 0 7 . Patients demonstrate clinical response eligible receive second round gene transfer discretion consultation FDA . Cohorts 3 patient receive escalate dos autologous dendritic cell-adenovirus CCL21 vaccine maximum tolerate dose ( MTD ) determine . An additional 12 patient treated MTD . Patients undergo blood sample collection baseline day 0 , 7 , 14 , 28 , 56 safety immunological study . Blood sample analyze mycoplasma PCR ; dendritic cell phenotype flow cytometry ; detection adenovirus CCL21 nest PCR ; adenoviral antibody ELISA . Patients also undergo tissue aspirate biopsy day 0 7 ( bronchoscopy CT-guided procedure ) . Tissue sample analyze immune-modulating cytokine ( i.e. , IFNγ , CXCL9 , CXCL10 ) quantitative RT-PCR ; detection tumor infiltrate leukocyte immunohistochemistry ; CD83+ DC , CXCR3 , CCR7 , CCL21 CD3+ T-cells , CD4 , CD8 flow cytometry ; determination tumor expression tumor-associated antigen RT-PCR ; evaluation immune modulation ELISPOT assay . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adults age 21 capable give informed consent Pathologically confirm nonsmall cell lung cancer ( NSCLC ) Stage IIIB , IV , recurrent disease Progressive disease despite one prior chemotherapy regimens standard care OR patient refuse standard chemotherapy Measurable metastatic disease RECIST guideline Patients major endobronchial lesion segmental , lobar , mainstem bronchus complete obstruction airway may eligible bronchoscopic injection provide evidence respiratory failure ( define SaO_2 &gt; 90 % room air , PCO_2 &lt; 45 mm Hg , FEV_1 &gt; 1.0 L ) Patients endobronchial lesion segmental bronchus variable stenosis ( completely obstruct ) amenable standard palliative airway treatment ( i.e. , laser stenting ) may eligible bronchoscopic injection evidence respiratory failure ( define SaO_2 &gt; 90 % room air , PCO_2 &lt; 45 mm Hg , FEV_1 &gt; 1.0 liter ) Patients bullous disease may undergo CTguided transthoracic injection provide targeted tumor intend needle path without cross bulla ECOG performance status 02 BUN ≤ 40 OR serum creatinine ≤ 2 Serum total bilirubin ≤ 1.5 OR serum transaminase ≤ 2.5 time upper limit normal ( ULN ) Negative pregnancy test Fertile patient must use effective contraception More 14 day since prior acute therapy viral , bacterial , fungal infection More 30 day since prior concurrent corticosteroid More 30 day since prior radiotherapy , chemotherapy , noncytotoxic investigational agent active CNS metastasis ( i.e. , progression CNS disease past 30 day without intervention ) evidence coagulopathy , define PT and/or PTT ≤ 1.5 time ULN OR platelets ≥ 100,000/mm^3 evidence leukoplakia , define absolute neutrophil count ≥ 1,500/mm^3 evidence respiratory failure ( define SaO_2 &gt; 90 % room air , PCO_2 &lt; 45 mm Hg , FEV_1 &gt; 1.0 L ) NYHA class IIIIV cardiac disease within past year myocardial infarction within past year comorbid disease medical condition would impair ability patient receive comply study protocol acute viral , bacterial , fungal infection require specific therapy HIV positivity hypersensitivity reagent use study sign symptom acute adenoviral infection ( i.e. , conjunctivitis document adenoviral upper respiratory infection ) prior concurrent evidence autoimmune disease pregnant nursing prior organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>